FGF21 via mitochondrial lipid oxidation promotes physiological vascularization in a mouse model of Phase I ROP.
Adiponectin
FGF21
Fatty acid oxidation
Hyperglycemia
Retinal vessel
Retinopathy of prematurity
Journal
Angiogenesis
ISSN: 1573-7209
Titre abrégé: Angiogenesis
Pays: Germany
ID NLM: 9814575
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
09
12
2022
accepted:
04
03
2023
medline:
10
7
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Hyperglycemia in early postnatal life of preterm infants with incompletely vascularized retinas is associated with increased risk of potentially blinding neovascular retinopathy of prematurity (ROP). Neovascular ROP (Phase II ROP) is a compensatory but ultimately pathological response to the suppression of physiological postnatal retinal vascular development (Phase I ROP). Hyperglycemia in neonatal mice which suppresses physiological retinal vascular growth is associated with decreased expression of systemic and retinal fibroblast growth factor 21 (FGF21). FGF21 administration promoted and FGF21 deficiency suppressed the physiological retinal vessel growth. FGF21 increased serum adiponectin (APN) levels and loss of APN abolished FGF21 promotion of physiological retinal vascular development. Blocking mitochondrial fatty acid oxidation also abolished FGF21 protection against delayed physiological retinal vessel growth. Clinically, preterm infants developing severe neovascular ROP (versus non-severe ROP) had a lower total lipid intake with more parenteral and less enteral during the first 4 weeks of life. Our data suggest that increasing FGF21 levels in the presence of adequate enteral lipids may help prevent Phase I retinopathy (and therefore prevent neovascular disease).
Identifiants
pubmed: 36943533
doi: 10.1007/s10456-023-09872-x
pii: 10.1007/s10456-023-09872-x
pmc: PMC10328855
doi:
Substances chimiques
fibroblast growth factor 21
0
Lipids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-421Subventions
Organisme : NEI NIH HHS
ID : R01EY017017
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY017017
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090255
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030904
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY032492
Pays : United States
Organisme : NEI NIH HHS
ID : R01EY017017
Pays : United States
Organisme : NEI NIH HHS
ID : R01EY017017
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Int J Cardiol. 2018 Jun 1;260:163-170
pubmed: 29519677
Nat Cell Biol. 2013 Jun;15(6):647-58
pubmed: 23604321
Biochim Biophys Acta. 2016 Aug;1862(8):1392-400
pubmed: 27155572
Am J Clin Nutr. 2015 Apr;101(4):879-88
pubmed: 25833984
Nat Med. 2016 Apr;22(4):439-45
pubmed: 26974308
Arch Ophthalmol. 2005 Jul;123(7):991-9
pubmed: 16009843
Pediatr Res. 2004 Nov;56(5):690-3
pubmed: 15371566
Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):358-368
pubmed: 32694348
Prog Retin Eye Res. 2017 Jan;56:32-57
pubmed: 27671171
JAMA Netw Open. 2021 Nov 1;4(11):e2135879
pubmed: 34812847
EMBO Mol Med. 2018 Jan;10(1):76-90
pubmed: 29180355
Exp Mol Med. 2021 Nov;53(11):1748-1758
pubmed: 34799683
Front Physiol. 2021 Feb 17;12:639920
pubmed: 33679452
Diabetes Care. 2003 Aug;26(8):2442-50
pubmed: 12882876
J Clin Endocrinol Metab. 2015 Jun;100(6):2380-7
pubmed: 25825949
Acta Diabetol. 2015 Aug;52(4):693-700
pubmed: 25604041
Cell Metab. 2016 Mar 8;23(3):427-40
pubmed: 26959184
Diabetes. 2018 May;67(5):974-985
pubmed: 29487115
Front Neurosci. 2022 Feb 17;16:830884
pubmed: 35250465
Pediatr Int. 2014 Oct;56(5):726-30
pubmed: 24803073
Clin Nutr ESPEN. 2017 Aug;20:17-23
pubmed: 29072164
Arch Ophthalmol. 2012 Aug;130(8):992-9
pubmed: 22491391
Int J Mol Sci. 2020 Feb 11;21(4):
pubmed: 32054022
Cell Metab. 2013 May 7;17(5):790-7
pubmed: 23663742
J Perinatol. 2011 Dec;31(12):749-56
pubmed: 21415837
Eur J Endocrinol. 2007 Aug;157(2):189-94
pubmed: 17656597
iScience. 2021 Mar 29;24(4):102376
pubmed: 33937726
J Clin Endocrinol Metab. 2014 Nov;99(11):E2198-206
pubmed: 25137423
J Perinatol. 2014 Jun;34(6):453-7
pubmed: 24674983
Arch Dis Child Fetal Neonatal Ed. 2007 Jul;92(4):F286-90
pubmed: 17074785
Elife. 2022 Nov 24;11:
pubmed: 36420952
J Perinatol. 2011 Apr;31(4):251-7
pubmed: 21233796
Mol Aspects Med. 2021 Dec;82:101038
pubmed: 34620506
Cell Rep. 2017 Feb 14;18(7):1606-1613
pubmed: 28199833
Diabetes. 2014 Dec;63(12):4057-63
pubmed: 25008183
Int J Obes (Lond). 2015 May;39(5):742-6
pubmed: 25599612
Cell Metab. 2013 Sep 3;18(3):333-40
pubmed: 24011069
JCI Insight. 2022 Mar 22;7(6):
pubmed: 35167498
Arch Ophthalmol. 2003 Dec;121(12):1684-94
pubmed: 14662586
Biol Neonate. 2006;89(1):56-9
pubmed: 16155387
Nutrients. 2018 Jan 31;10(2):
pubmed: 29385065
BMC Pediatr. 2013 May 16;13:78
pubmed: 23679669
Cell Death Discov. 2020 May 1;6:32
pubmed: 32377395
Lancet. 2013 Oct 26;382(9902):1445-57
pubmed: 23782686
Metabol Open. 2020 Mar 05;5:100030
pubmed: 32812922
Nutrients. 2022 Mar 23;14(7):
pubmed: 35405946
J Perinatol. 2003 Apr-May;23(3):186-94
pubmed: 12732854
BMJ Open Diabetes Res Care. 2021 Mar;9(1):
pubmed: 33789910
J Perinatol. 2006 Dec;26(12):737-41
pubmed: 16929343
Front Physiol. 2019 Apr 17;10:419
pubmed: 31057418
Sci Rep. 2015 Mar 13;5:9091
pubmed: 25766465
J Clin Invest. 2015 Nov 03;125(12):4601-11
pubmed: 26529252
J Clin Endocrinol Metab. 2004 Aug;89(8):4031-6
pubmed: 15292345
Curr Opin Pediatr. 2011 Apr;23(2):173-8
pubmed: 21150442
Sci Rep. 2015 Sep 02;5:13717
pubmed: 26329882
Nutr Metab (Lond). 2021 Apr 13;18(1):40
pubmed: 33849585
Horm Res Paediatr. 2014;82(5):324-31
pubmed: 25300595
Invest Ophthalmol Vis Sci. 2020 Feb 7;61(2):12
pubmed: 32049343
Neonatology. 2011;100(1):93-8
pubmed: 21273794
Am J Physiol Cell Physiol. 2019 Nov 1;317(5):C1034-C1047
pubmed: 31483704
JPEN J Parenter Enteral Nutr. 2019 Jan;43(1):152-161
pubmed: 29679529